On this episode of the 40+ Fitness Podcast, Coach Allan breaks down the fight playing out right now in Washington, DC, between GLP-1 medications and peptides.
The two keep getting mentioned in the same breath, but they sit on opposite sides of the evidence line. GLP-1s like semaglutide and tirzepatide are tested medications with known dosing and documented side effects. Peptides like BPC-157 and TB-500, the so-called Wolverine stack, are not approved for human use and live in a gray market built mostly on rat studies and anecdote.
Coach Allan walks through the recent FDA Pharmacy Compounding Advisory Committee panel that recommended approving 6 of 7 peptides even after the agency's own scientists raised safety concerns, and he points out what it means for you.
Time Stamps:
02:54 GLP-1s and peptides, framing the fight
04:26 Peptides and the gray market
05:20 The cheating debate around weight-loss drugs
06:07 The peptides: AOD-9604, BPC-157, TB-500
07:00 Branding and hype: the Wolverine stack
08:50 How both sides market GLP-1s and peptides
09:54 RFK Jr. and what the FDA is for
11:04 Follow the science, not the phrases
12:57 Off-label prescribing and thin peptide data
14:34 Gray market and inconsistent manufacturing
15:47 The FDA compounding panel meets
16:32 FDA scientists warn against approval
17:43 The panel's conflict of interest and 6-of-7 recommendation
19:50 The Joe Rogan ivermectin parallel
22:20 Peptides, cancer risk, and personal caution
23:11 The N=1 experiment and its limits
26:33 Making the decision that's right for you
Links
- Work with Allan one-on-one (a few coaching slots are open right now): coach@40plusfitness.com
- 40+ Fitness: https://40plusfitness.com